Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 38162667)

  • 21. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
    Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
    Zhang S; Wang W; Xu C; Zhang Y; Cai X; Wang Q; Song Z; Li Z; Yu J; Zhong W; Wang Z; Liu J; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Dong X; Pang F; Wang K; Yao C; Lin G; Li S; Yang Z; Luo J; Jia H; Nie X; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Xia Y; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Gao W; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Wan B; Lv D; Yu G; Shi L; Xia Y; Gao F; Zhang X; Xu T; Zhou W; Wang H; Liu Z; Yang N; Wu L; Wang Q; Wang G; Hong Z; Wang J; Fang M; Fang Y; Zhang Y; Song Y; Ma S; Fang W; Lu Y
    Thorac Cancer; 2023 Jan; 14(1):91-104. PubMed ID: 36444143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy.
    Falk M; Willing E; Schmidt S; Schatz S; Galster M; Tiemann M; Ficker JH; Brueckl WM
    Curr Oncol; 2023 Jan; 30(2):1692-1698. PubMed ID: 36826091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer.
    Rassy E; Rached L; Pistilli B
    Breast; 2022 Dec; 66():217-226. PubMed ID: 36334569
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
    Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
    Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
    Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
    Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
    Belluomini L; Avancini A; Sposito M; Milella M; Rossi A; Pilotto S
    Expert Opin Biol Ther; 2023; 23(11):1077-1087. PubMed ID: 36995069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].
    Wang N; Zhao L; Zhang D; Jia Y; Kong F
    Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):214-218. PubMed ID: 35340165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic
    Yu HA; Yang JC; Hayashi H; Goto Y; Felip E; Reck M; Vigliotti M; Dong Q; Cantero F; Fan PD; Kanai M; Sternberg DW; Jänne PA
    Future Oncol; 2023 Jun; 19(19):1319-1329. PubMed ID: 37212796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-drug conjugates for lung cancer in the era of personalized oncology.
    Ricciuti B; Lamberti G; Andrini E; Genova C; De Giglio A; Bianconi V; Sahebkar A; Chiari R; Pirro M
    Semin Cancer Biol; 2021 Feb; 69():268-278. PubMed ID: 31899248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting HER2 alterations in non-small cell lung cancer: Therapeutic breakthrough and challenges.
    Yu Y; Yang Y; Li H; Fan Y
    Cancer Treat Rev; 2023 Mar; 114():102520. PubMed ID: 36738637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.
    Ahmed Y; Berenguer-Pina JJ; Mahgoub T
    Oncology; 2021; 99(10):673-680. PubMed ID: 34280931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Next-generation antibody-drug conjugates for breast cancer: Moving beyond HER2 and TROP2.
    Schlam I; Moges R; Morganti S; Tolaney SM; Tarantino P
    Crit Rev Oncol Hematol; 2023 Oct; 190():104090. PubMed ID: 37562695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
    Takakura T; Yamamoto N
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.
    Passaro A; Jänne PA; Peters S
    J Clin Oncol; 2023 Jul; 41(21):3747-3761. PubMed ID: 37224424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.
    Saini KS; Punie K; Twelves C; Bortini S; de Azambuja E; Anderson S; Criscitiello C; Awada A; Loi S
    Expert Opin Biol Ther; 2021 Jul; 21(7):945-962. PubMed ID: 34043927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
    Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel treatment approaches for HER2 positive solid tumors (excluding breast cancer).
    Gaye E; Penel N; Lebellec L
    Curr Opin Oncol; 2022 Sep; 34(5):570-574. PubMed ID: 35943440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-drug conjugates in lung cancer: dawn of a new era?
    Coleman N; Yap TA; Heymach JV; Meric-Bernstam F; Le X
    NPJ Precis Oncol; 2023 Jan; 7(1):5. PubMed ID: 36631624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.